{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:59:03Z","timestamp":1786593543816,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004817","name":"Lund University Medical Faculty Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004817","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016409","name":"Gyllenstiernska Krapperupsstiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003461","name":"Gunnar Nilssons Cancerstiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009736","name":"Allm\u00e4nna Sjukhusets i Malm\u00f6 Stiftelse f\u00f6r Bek\u00e4mpande av Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004635","name":"Fru Berta Kamprads Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004635","id-type":"DOI","asserted-by":"publisher"}]},{"name":"governmental funding for clinical research , Sweden"},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metastatic breast cancer (MBC) is a challenging disease, and despite new therapies, prognosis is still poor for a majority of patients. There is a clinical need for improved prognostication where immuno-oncology markers can provide important information. The aim of this study was to evaluate serum immuno-oncology markers in MBC patients and their respective relevance for prediction of survival.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>We investigated a broad panel of 92 immuno-oncology proteins in serum from 136 MBC patients included in a prospective observational study (NCT01322893) with long-term follow-up. Serum samples were collected before start of systemic therapy and analyzed using multiplex proximity extension assay (Olink Target 96 Immuno-Oncology panel). Multiple machine learning techniques were used to identify serum markers with highest importance for prediction of overall and progression-free survival (OS and PFS), and associations to survival were further evaluated using Cox regression analyses. False discovery rate was then used to adjust for multiple comparisons.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Using random forest and random survival forest analyses, we identified the top nine and ten variables of highest predictive importance for OS and PFS, respectively. Cox regression analyses revealed significant associations (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.005) of higher serum levels of IL-8, IL-10 and CAIX with worse OS in multivariable analyses, adjusted for established clinical prognostic factors including circulating tumor cells (CTCs). Similarly, high serum levels of IL-8, IL-10, ADA and CASP8 significantly associated with worse PFS. Interestingly, high serum levels of FasL significantly associated with improved OS and PFS. In addition, CSF-1, IL-6, MUC16, TFNSFR4 and CD244 showed suggestive evidence (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) for an association to survival in multivariable analyses. After correction for multiple comparisons, IL-8 still showed strong evidence for correlation to survival.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>To conclude, we found six serum immuno-oncology markers that were significantly associated with OS and\/or PFS in MBC patients, independently of other established prognostic factors including CTCs. Furthermore, an additional five serum immuno-oncology markers provided suggestive evidence for an independent association to survival. These findings highlight the relevance of immuno-oncology serum markers in MBC patients and support their usefulness for improved prognostication.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Clinical Trials (NCT01322893), registered March 25, 2011.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-023-01631-6","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T14:08:23Z","timestamp":1679407703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study"],"prefix":"10.1186","volume":"25","clinical-trial-number":[{"clinical-trial-number":"nct01322893","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Frida Bj\u00f6rk","family":"Gunnarsdottir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r-Ola","family":"Bendahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Benfeitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bergenfelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"issue":"12","key":"1631_CR1","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623\u201349. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010.","journal-title":"Ann Oncol"},{"issue":"6","key":"1631_CR2","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.3892\/ijo.2012.1667","volume":"41","author":"LG Perez-Rivas","year":"2012","unstructured":"Perez-Rivas LG, Jerez JM, Fernandez-De Sousa CE, de Luque V, Quero C, Pajares B, et al. Serum protein levels following surgery in breast cancer patients: a protein microarray approach. Int J Oncol. 2012;41(6):2200\u20136. https:\/\/doi.org\/10.3892\/ijo.2012.1667.","journal-title":"Int J Oncol"},{"key":"1631_CR3","doi-asserted-by":"publisher","first-page":"155487","DOI":"10.1016\/j.cyto.2021.155487","volume":"142","author":"JW Kim","year":"2021","unstructured":"Kim JW, Lee S, Kim HS, Choi YJ, Yoo J, Park KU, et al. Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10\u201313). Cytokine. 2021;142:155487. https:\/\/doi.org\/10.1016\/j.cyto.2021.155487.","journal-title":"Cytokine"},{"issue":"4","key":"1631_CR4","doi-asserted-by":"publisher","first-page":"e522","DOI":"10.1016\/j.clbc.2019.03.006","volume":"19","author":"L Tiainen","year":"2019","unstructured":"Tiainen L, H\u00e4m\u00e4l\u00e4inen M, Luukkaala T, Tanner M, Lahdenper\u00e4 O, Vihinen P, et al. Low plasma IL-8 levels during chemotherapy are predictive of excellent long-term survival in metastatic breast cancer. Clin Breast Cancer. 2019;19(4):e522\u201333. https:\/\/doi.org\/10.1016\/j.clbc.2019.03.006.","journal-title":"Clin Breast Cancer"},{"key":"1631_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cca.2017.04.023","volume":"470","author":"W Wang","year":"2017","unstructured":"Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, et al. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Clin Chim Acta. 2017;470:51\u20135. https:\/\/doi.org\/10.1016\/j.cca.2017.04.023.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"1631_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/annonc\/mdr154","volume":"23","author":"R Yerushalmi","year":"2012","unstructured":"Yerushalmi R, Tyldesley S, Kennecke H, Speers C, Woods R, Knight B, et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol. 2012;23(2):338\u201345. https:\/\/doi.org\/10.1093\/annonc\/mdr154.","journal-title":"Ann Oncol"},{"issue":"1","key":"1631_CR7","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/s41598-017-01268-4","volume":"7","author":"AS Noman","year":"2017","unstructured":"Noman AS, Uddin M, Chowdhury AA, Nayeem MJ, Raihan Z, Rashid MI, et al. Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer. Sci Rep. 2017;7(1):1796. https:\/\/doi.org\/10.1038\/s41598-017-01268-4.","journal-title":"Sci Rep"},{"issue":"6","key":"1631_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1089\/152581601317210854","volume":"10","author":"M Bewick","year":"2001","unstructured":"Bewick M, Conlon M, Parissenti AM, Lee H, Zhang L, Gl\u00fcck S, et al. Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J Hematother Stem Cell Res. 2001;10(6):759\u201368. https:\/\/doi.org\/10.1089\/152581601317210854.","journal-title":"J Hematother Stem Cell Res"},{"issue":"11","key":"1631_CR9","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/sj.bjc.6600956","volume":"88","author":"T Bachelot","year":"2003","unstructured":"Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer. 2003;88(11):1721\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6600956.","journal-title":"Br J Cancer"},{"issue":"21","key":"1631_CR10","doi-asserted-by":"publisher","first-page":"7157","DOI":"10.1158\/1078-0432.Ccr-04-0812","volume":"10","author":"IH Benoy","year":"2004","unstructured":"Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharp\u00e9 S, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004;10(21):7157\u201362. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-0812.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1631_CR11","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bj\u00f6rkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4):e95192. https:\/\/doi.org\/10.1371\/journal.pone.0095192.","journal-title":"PLoS ONE"},{"issue":"1","key":"1631_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41523-021-00287-9","volume":"7","author":"R Barroso-Sousa","year":"2021","unstructured":"Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, et al. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer. 2021;7(1):110. https:\/\/doi.org\/10.1038\/s41523-021-00287-9.","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"1631_CR13","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/ejhf.1758","volume":"22","author":"J Tromp","year":"2020","unstructured":"Tromp J, Boerman LM, Sama IE, Maass S, Maduro JH, Hummel YM, et al. Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls. Eur J Heart Fail. 2020;22(7):1239\u201346. https:\/\/doi.org\/10.1002\/ejhf.1758.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"1631_CR14","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41430-019-0396-y","volume":"73","author":"G Lindahl","year":"2019","unstructured":"Lindahl G, Abrahamsson A, Dabrosin C. Dietary flaxseed and tamoxifen affect the inflammatory microenvironment in vivo in normal human breast tissue of postmenopausal women. Eur J Clin Nutr. 2019;73(9):1250\u20139. https:\/\/doi.org\/10.1038\/s41430-019-0396-y.","journal-title":"Eur J Clin Nutr"},{"issue":"2","key":"1631_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/1878-0261.12410","volume":"13","author":"B Franz\u00e9n","year":"2019","unstructured":"Franz\u00e9n B, Alexeyenko A, Kamali-Moghaddam M, Hatschek T, Kanter L, Ramqvist T, et al. Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer. Mol Oncol. 2019;13(2):376\u201391. https:\/\/doi.org\/10.1002\/1878-0261.12410.","journal-title":"Mol Oncol"},{"key":"1631_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061305","author":"S Batalha","year":"2021","unstructured":"Batalha S, Ferreira S, Brito C. The peripheral immune landscape of breast cancer: clinical findings and in vitro models for biomarker discovery. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13061305.","journal-title":"Cancers"},{"key":"1631_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcancer.2020.06.016","volume":"79","author":"N Gaynor","year":"2022","unstructured":"Gaynor N, Crown J, Collins DM. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. Semin Cancer Biol. 2022;79:44\u201357. https:\/\/doi.org\/10.1016\/j.semcancer.2020.06.016.","journal-title":"Semin Cancer Biol"},{"key":"1631_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/bctt.S293597","volume":"14","author":"NA Bagegni","year":"2022","unstructured":"Bagegni NA, Davis AA, Clifton KK, Ademuyiwa FO. Targeted treatment for high-risk early-stage triple-negative breast cancer: spotlight on pembrolizumab. Breast Cancer. 2022;14:113\u201323. https:\/\/doi.org\/10.2147\/bctt.S293597.","journal-title":"Breast Cancer"},{"issue":"1","key":"1631_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13058-018-0976-0","volume":"20","author":"AM Larsson","year":"2018","unstructured":"Larsson AM, Jansson S, Bendahl PO, Levin Tykjaer J\u00f6rgensen C, Loman N, Graffman C, et al. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 2018;20(1):48. https:\/\/doi.org\/10.1186\/s13058-018-0976-0.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1631_CR20","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.1038\/s41598-020-61416-1","volume":"10","author":"AM Larsson","year":"2020","unstructured":"Larsson AM, Bendahl PO, Aaltonen K, Jansson S, Forsare C, Bergqvist M, et al. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer. Sci Rep. 2020;10(1):4484. https:\/\/doi.org\/10.1038\/s41598-020-61416-1.","journal-title":"Sci Rep"},{"key":"1631_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071592","author":"CLT J\u00f8rgensen","year":"2021","unstructured":"J\u00f8rgensen CLT, Larsson AM, Forsare C, Aaltonen K, Jansson S, Bradshaw R, et al. PAM50 Intrinsic subtype profiles in primary and metastatic breast cancer show a significant shift toward more aggressive subtypes with prognostic implications. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13071592.","journal-title":"Cancers"},{"key":"1631_CR22","doi-asserted-by":"publisher","first-page":"20.10.1","DOI":"10.1002\/0471142727.mb2010s109","volume":"109","author":"T Ebai","year":"2015","unstructured":"Ebai T, Kamali-Moghaddam M, Landegren U. Parallel protein detection by solid-phase proximity ligation assay with real-time PCR or sequencing. Curr Protoc Mol Biol. 2015;109:20.10.1-20.10.25. https:\/\/doi.org\/10.1002\/0471142727.mb2010s109.","journal-title":"Curr Protoc Mol Biol"},{"key":"1631_CR23","unstructured":"Korobov M. Permutation Importance. 2016. <https:\/\/eli5.readthedocs.io\/en\/latest\/blackbox\/permutation_importance.html>."},{"key":"1631_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1741-7015-10-51","volume":"10","author":"DG Altman","year":"2012","unstructured":"Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 2012;10:51. https:\/\/doi.org\/10.1186\/1741-7015-10-51.","journal-title":"BMC Med"},{"issue":"1","key":"1631_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41562-017-0189-z","volume":"2","author":"DJ Benjamin","year":"2018","unstructured":"Benjamin DJ, Berger JO, Johannesson M, Nosek BA, Wagenmakers EJ, Berk R, et al. Redefine statistical significance. Nat Hum Behav. 2018;2(1):6\u201310. https:\/\/doi.org\/10.1038\/s41562-017-0189-z.","journal-title":"Nat Hum Behav"},{"issue":"1","key":"1631_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B. 1995;57(1):289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x.","journal-title":"J Roy Stat Soc Ser B"},{"issue":"6824","key":"1631_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/35065016","volume":"410","author":"A M\u00fcller","year":"2001","unstructured":"M\u00fcller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50\u20136. https:\/\/doi.org\/10.1038\/35065016.","journal-title":"Nature"},{"issue":"4","key":"1631_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/bcr3436","volume":"15","author":"JK Singh","year":"2013","unstructured":"Singh JK, Sim\u00f5es BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013;15(4):210. https:\/\/doi.org\/10.1186\/bcr3436.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"1631_CR29","first-page":"61","volume":"13","author":"OI Ahmed","year":"2006","unstructured":"Ahmed OI, Adel AM, Diab DR, Gobran NS. Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol. 2006;13(2):61\u20138.","journal-title":"Egypt J Immunol"},{"key":"1631_CR30","first-page":"82","volume":"48","author":"L Koz\u0142owski","year":"2003","unstructured":"Koz\u0142owski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003;48:82\u20134.","journal-title":"Rocz Akad Med Bialymst"},{"issue":"49","key":"1631_CR31","doi-asserted-by":"publisher","first-page":"e8840","DOI":"10.1097\/md.0000000000008840","volume":"96","author":"H Wang","year":"2017","unstructured":"Wang H, Yang X. Association between serum cytokines and progression of breast cancer in Chinese population. Medicine. 2017;96(49):e8840. https:\/\/doi.org\/10.1097\/md.0000000000008840.","journal-title":"Medicine"},{"key":"1631_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10010078","author":"M Paccagnella","year":"2022","unstructured":"Paccagnella M, Abbona A, Michelotti A, Geuna E, Ruatta F, Landucci E, et al. Circulating cytokines in metastatic breast cancer patients select different prognostic groups and patients who might benefit from treatment beyond progression. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10010078.","journal-title":"Vaccines"},{"issue":"4","key":"1631_CR33","doi-asserted-by":"publisher","first-page":"R71","DOI":"10.1186\/bcr2916","volume":"13","author":"V M\u00fcller","year":"2011","unstructured":"M\u00fcller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, et al. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. Breast Cancer Res. 2011;13(4):R71. https:\/\/doi.org\/10.1186\/bcr2916.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"1631_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.31557\/apjcp.2020.21.3.629","volume":"21","author":"I Gunawan","year":"2020","unstructured":"Gunawan I, Hatta M, Benyamin AF, Islam AA. The hypoxic response expression as a survival biomarkers in treatment-naive advanced breast cancer. Asian Pac J Cancer Prev. 2020;21(3):629\u201337. https:\/\/doi.org\/10.31557\/apjcp.2020.21.3.629.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"1631_CR35","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10549-017-4273-x","volume":"164","author":"D Ho","year":"2017","unstructured":"Ho D, Huang J, Chapman JW, Leitzel K, Ali SM, Shepherd L, et al. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). Breast Cancer Res Treat. 2017;164(3):571\u201380. https:\/\/doi.org\/10.1007\/s10549-017-4273-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"28","key":"1631_CR36","doi-asserted-by":"publisher","first-page":"24856","DOI":"10.18632\/oncotarget.4498","volume":"6","author":"C Ward","year":"2015","unstructured":"Ward C, Meehan J, Mullen P, Supuran C, Dixon JM, Thomas JS, et al. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget. 2015;6(28):24856\u201370. https:\/\/doi.org\/10.18632\/oncotarget.4498.","journal-title":"Oncotarget"},{"key":"1631_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23051045","author":"S Singh","year":"2018","unstructured":"Singh S, Lomelino CL, Mboge MY, Frost SC, McKenna R. Cancer drug development of carbonic anhydrase inhibitors beyond the active site. Molecules. 2018. https:\/\/doi.org\/10.3390\/molecules23051045.","journal-title":"Molecules"},{"issue":"6","key":"1631_CR38","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1530\/erc-13-0198","volume":"20","author":"S Aharinejad","year":"2013","unstructured":"Aharinejad S, Salama M, Paulus P, Zins K, Berger A, Singer CF. Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer. Endocr Relat Cancer. 2013;20(6):777\u201383. https:\/\/doi.org\/10.1530\/erc-13-0198.","journal-title":"Endocr Relat Cancer"},{"key":"1631_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073764","author":"B Kutryb-Zajac","year":"2021","unstructured":"Kutryb-Zajac B, Harasim G, Jedrzejewska A, Krol O, Braczko A, Jablonska P, et al. Macrophage-derived adenosine deaminase 2 correlates with M2 macrophage phenotype in triple negative breast cancer. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22073764.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1631_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12969-016-0111-7","volume":"14","author":"R Caorsi","year":"2016","unstructured":"Caorsi R, Penco F, Schena F, Gattorno M. Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatr Rheumatol Online J. 2016;14(1):51. https:\/\/doi.org\/10.1186\/s12969-016-0111-7.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"1631_CR41","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1307361","volume":"370","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1307361.","journal-title":"N Engl J Med"},{"issue":"2","key":"1631_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1189\/jlb.1109764","volume":"88","author":"AV Zavialov","year":"2010","unstructured":"Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol. 2010;88(2):279\u201390. https:\/\/doi.org\/10.1189\/jlb.1109764.","journal-title":"J Leukoc Biol"},{"issue":"Pt 1","key":"1631_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1042\/bj20050683","volume":"391","author":"AV Zavialov","year":"2005","unstructured":"Zavialov AV, Engstr\u00f6m A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J. 2005;391(Pt 1):51\u20137. https:\/\/doi.org\/10.1042\/bj20050683.","journal-title":"Biochem J"},{"issue":"3","key":"1631_CR44","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10495-016-1323-5","volume":"22","author":"X Pu","year":"2017","unstructured":"Pu X, Storr SJ, Zhang Y, Rakha EA, Green AR, Ellis IO, et al. Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. Apoptosis. 2017;22(3):357\u201368. https:\/\/doi.org\/10.1007\/s10495-016-1323-5.","journal-title":"Apoptosis"},{"issue":"6","key":"1631_CR45","doi-asserted-by":"publisher","first-page":"100969","DOI":"10.1016\/j.accpm.2021.100969","volume":"40","author":"L Lorente","year":"2021","unstructured":"Lorente L, Mart\u00edn MM, Gonz\u00e1lez-Rivero AF, Ramos-G\u00f3mez L, Sole-Violan J, C\u00e1ceres JJ, et al. Mortality of spontaneous intracerebral haemorrhage patients and high serum caspase-8 concentrations. Anaesth Crit Care Pain Med. 2021;40(6):100969. https:\/\/doi.org\/10.1016\/j.accpm.2021.100969.","journal-title":"Anaesth Crit Care Pain Med"},{"key":"1631_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.medin.2020.06.016","author":"L Lorente","year":"2020","unstructured":"Lorente L, Mart\u00edn MM, Ortiz-L\u00f3pez R, Gonz\u00e1lez-Rivero AF, P\u00e9rez-Cejas A, Mart\u00edn M, et al. Blood caspase-8 concentrations and mortality among septic patients. Med Intensiva. 2020. https:\/\/doi.org\/10.1016\/j.medin.2020.06.016.","journal-title":"Med Intensiva"},{"key":"1631_CR47","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.3389\/fimmu.2018.02809","volume":"9","author":"L Agresta","year":"2018","unstructured":"Agresta L, Hoebe KHN, Janssen EM. The emerging role of CD244 signaling in immune cells of the tumor microenvironment. Front Immunol. 2018;9:2809. https:\/\/doi.org\/10.3389\/fimmu.2018.02809.","journal-title":"Front Immunol"},{"key":"1631_CR48","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20201054","author":"J Fang","year":"2020","unstructured":"Fang J, Chen F, Liu D, Gu F, Chen Z, Wang Y. Prognostic value of immune checkpoint molecules in breast cancer. 2020. Biosci Rep. https:\/\/doi.org\/10.1042\/bsr20201054."},{"key":"1631_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246259","author":"RDW Vaes","year":"2021","unstructured":"Vaes RDW, Reynders K, Sprooten J, Nevola KT, Rouschop KMA, Vooijs M, et al. Identification of potential prognostic and predictive immunological biomarkers in patients with stage I and stage III non-small cell lung cancer (NSCLC): a prospective exploratory study. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13246259.","journal-title":"Cancers"},{"key":"1631_CR50","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cca.2014.08.012","volume":"438","author":"CY Kadam","year":"2015","unstructured":"Kadam CY, Abhang SA. Serum levels of soluble Fas ligand, granzyme B and cytochrome c during adjuvant chemotherapy of breast cancer. Clin Chim Acta. 2015;438:98\u2013102. https:\/\/doi.org\/10.1016\/j.cca.2014.08.012.","journal-title":"Clin Chim Acta"},{"issue":"11","key":"1631_CR51","first-page":"3529","volume":"5","author":"T Ueno","year":"1999","unstructured":"Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res. 1999;5(11):3529\u201333.","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-023-01631-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-023-01631-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-023-01631-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T14:12:17Z","timestamp":1679407937000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-023-01631-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1631"],"URL":"https:\/\/doi.org\/10.1186\/s13058-023-01631-6","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"20 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee at Lund University, Lund, Sweden (LU. 2010\/135). All included patients provided written informed consent for participation. The research was performed in accordance with the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All included patients provided written informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RB was an employee at NBIS at the time of data analyses. RB is currently an employee of Chiesi Farmaceutici S.p.A. and does not hold Chiesi Farmaceutici S.p.A. stocks or equity shares. Chiesi Farmaceutici S.p.A. was not involved with the current study. FBG was an employee at Lund University at the time of data analyses and drafting the manuscript. FBG is currently an employee at Alligator Bioscience and does not hold Alligator Bioscience stocks or equity shares, and Alligator Bioscience was not involved with the current study. All other authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}